Comparable stake leader
Forbion Growth Opportunities Fund II Cooperatief U.A.
SEC ownership of BICYCLE THERAPEUTICS PLC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001761612.
Disclosed value leader
BAKER BROS. ADVISORS LP
Comparable rows
6/50
Latest evidence
02 Oct 2026
- Public ticker
- BCYC on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Forbion Growth Opportunities Fund II Cooperatief U.A.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
6 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Forbion Growth Opportunities Fund II Cooperatief U.A.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
02 Oct 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001761612
- Issuer location
- Cambridge, United Kingdom
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of BICYCLE THERAPEUTICS PLC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Forbion Growth Opportunit...
Disclosed value leader
BAKER BROS. ADVISORS LP
Comparable rows
6/50
Latest evidence
02 Oct 2026
13D/G
3/4/5
13F
Lead comparable stake: 7.3%
44 rows are not safely comparable across share classes.
13D/G row: Forbion Growth Opportunities Fund II Cooperatief U.A.
Showing 1-8 of 50 holder rows.
Quick read
Forbion Growth Opportunities Fund II Cooperatief U.A. leads the comparable SEC ownership view at 7.3%.
6 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Forbion Growth Opportunities Fund II Cooperatief U.A.'s linked filing trail.
Comparable ownership
Top 5
Forbion Growth Opportunities Fund...
7.3%
ARMISTICE CAPITAL, LLC
6.7%
Long Focus Capital Management, LLC
6.6%
Point72 Asset Management, L.P.
3.9%
Invus Global Management, LLC
3.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Forbion Growth Opportunities Fund II Cooperatief U.A. |
13D/G
|
7.3%
Reported 13D/G
· 21 Nov 2024
|
$28,343,629
3,452,330 shares
|
$0 | 21 Nov 2024 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
6.7%
Reported 13D/G
· 30 Jun 2026
|
$14,543,440
3,398,000 shares
|
$0 | 30 Jun 2026 |
| Long Focus Capital Management, LLC |
13D/G
|
6.6%
Reported 13D/G
· 31 Mar 2026
|
$16,487,221
3,310,687 shares
|
$0 | 31 Mar 2026 |
| Point72 Asset Management, L.P. |
13D/G
|
3.9%
Reported 13D/G
· 30 Jun 2025
|
$14,882,536
1,860,317 shares
|
-$15,032,008 | 30 Jun 2025 |
| Invus Global Management, LLC |
13D/G
Raymond Debbane
|
3.1%
Reported 13D/G
· 31 Mar 2026
|
$7,773,192
1,560,882 shares
|
-$7,909,072 | 31 Mar 2026 |
| Deep Track Capital, LP |
13D/G
|
2.4%
Reported 13D/G
· 30 Jun 2025
|
$9,625,952
1,203,244 shares
|
-$12,943,416 | 30 Jun 2025 |
| BAKER BROS. ADVISORS LP |
3/4/5
Director, 10%+ Owner
|
—
mixed-class rows
|
$153,412,999
10,056,674 shares
mixed-class rows
|
— | 02 Jan 2026 |
| Kate Bingham |
3/4/5
Director
|
—
denominator unverified
|
$32,731,633
1,870,379 shares
|
— | 13 Jul 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$517,420.
Buys
$0
Insiders: 0
Sells
$517,420
Insiders: 8
Net
-$517,420
Shares: -94,654
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 94,654
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 16,823 | $0 | $58,726 | -$58,726 |
| 3-6 | 0 | 14,129 | $0 | $60,461 | -$60,461 |
| 6-9 | 0 | 14,168 | $0 | $69,977 | -$69,977 |
| 9-12 | 0 | 49,534 | $0 | $328,256 | -$328,256 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 26 reporting-owner rows connected to BICYCLE THERAPEUTICS PLC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
26
Largest Forms 3/4/5 holder
BAKER BROS. ADVISORS LP
Net 12M change
-$517.42K
Full value: -$517,422 · USD · 12-month changeLatest report
02 Oct 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Director, 10%+ Owner | $153,412,999 | Mixed | 02 Jan 2026 | ||
| Kate Bingham | Director | $32,731,633 | Mixed | 13 Jul 2021 | ||
| Kevin Lee | CHIEF EXECUTIVE OFFICER, Director | $2,127,241 | -$239,111 | -10% | Filing P/S | 02 Oct 2026 |
| Gregory Paul Winter | Director | $1,390,722 | Mixed | 02 Jan 2026 | ||
| Nicholas Keen | Chief Scientific Officer | $1,355,631 | Mixed | 03 Jul 2024 | ||
| Santiago Arroyo | Chief Development Officer | $973,013 | Filing P/S | 02 Jan 2025 | ||
| Alistair Milnes | Chief Operating Officer | $883,191 | -$44,127 | -4.8% | Filing P/S | 02 Jan 2026 |
| Nigel Crockett | Chief Business Officer | $753,032 | Filing P/S | 02 Jan 2025 | ||
| Pierre Legault | Director | $690,000 | Mixed | 02 Jan 2025 | ||
| Dominic Smethurst | Chief Medical Officer | $642,233 | Mixed | 03 Jan 2023 | ||
| Richard N. Kender | Director | $570,860 | Mixed | 02 Jan 2025 | ||
| Alethia Young | Chief Financial Officer | $569,509 | -$50,489 | -8.1% | Filing P/S | 02 Jan 2026 |
| Michael Skynner | Chief Scientific Officer | $552,371 | -$72,447 | -12% | Filing P/S | 02 Oct 2026 |
| Lee Kalowski | President and CFO | $530,408 | Mixed | 03 Apr 2023 | ||
| Jennifer Scott Perry | Chief Operating Officer | $338,695 | -$14,355 | -4.1% | Filing P/S | 02 Oct 2026 |
| Michael Charles Ferguson Hannay | Chief Prod & Supply Chain Off | $330,442 | -$57,075 | -15% | Filing P/S | 02 Oct 2026 |
| Veronica Gh Jordan | Director | $293,125 | Mixed | 02 Jan 2024 | ||
| Janice Bourque | Director | $230,103 | Mixed | 02 Jan 2026 | ||
| Jose-Carlos Gutierrez-Ramos | Director | $230,103 | Mixed | 02 Jan 2026 | ||
| Travis Alvin Thompson | Chief Financial Officer | $230,082 | -$27,912 | -11% | Filing P/S | 02 Oct 2026 |
Recent insider transactions for BICYCLE THERAPEUTICS PLC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jennifer Scott Perry | BCYC | Ordinary Shares | Sale | -0.4% | -$1,339 | $3.76 | -356 | 89,602 | 05 Oct 2026 | Direct |
| Michael Skynner | BCYC | Ordinary Shares | Sale | -0.32% | -$1,796 | $3.57 | -503 | 154,726 | 05 Oct 2026 | Direct |
| Michael Charles Ferguson Hannay | BCYC | Ordinary Shares | Sale | -0.26% | -$864 | $3.57 | -242 | 92,561 | 05 Oct 2026 | Direct |
| Kevin Lee | BCYC | Ordinary Shares | Sale | -0.27% | -$5,848 | $3.57 | -1,638 | 595,866 | 05 Oct 2026 | Direct |
| Travis Alvin Thompson | BCYC | Ordinary Shares | Sale | -0.12% | -$282 | $3.57 | -79 | 64,449 | 05 Oct 2026 | Direct |
| Robert Charles Swanton | BCYC | Ordinary Shares | Sale | -17.9% | -$11,906 | $3.47 | -3,431 | 15,782 | 02 Oct 2026 | Direct |
| Michael Skynner | BCYC | Ordinary Shares | Sale | -1.24% | -$6,739 | $3.47 | -1,942 | 155,229 | 02 Oct 2026 | Direct |
| Michael Charles Ferguson Hannay | BCYC | Ordinary Shares | Sale | -1.67% | -$5,455 | $3.47 | -1,572 | 92,803 | 02 Oct 2026 | Direct |
| Kevin Lee | BCYC | Ordinary Shares | Sale | -1.02% | -$21,399 | $3.47 | -6,167 | 597,504 | 02 Oct 2026 | Direct |
| Travis Alvin Thompson | BCYC | Ordinary Shares | Sale | -1.37% | -$3,099 | $3.47 | -893 | 64,528 | 02 Oct 2026 | Direct |
| Travis Alvin Thompson | BCYC | Employee Stock Option (right to buy) | Award | 60,000 | 60,000 | 15 Jul 2026 | Direct | |||
| Michael Charles Ferguson Hannay | BCYC | Employee Stock Option (right to buy) | Award | 60,000 | 60,000 | 15 Jul 2026 | Direct | |||
| Michael Skynner | BCYC | Employee Stock Option (right to buy) | Award | 60,000 | 60,000 | 15 Jul 2026 | Direct | |||
| Jennifer Scott Perry | BCYC | Employee Stock Option (right to buy) | Award | 60,000 | 60,000 | 15 Jul 2026 | Direct | |||
| Jennifer Scott Perry | BCYC | Ordinary Shares | Sale | -0.41% | -$1,631 | $4.34 | -376 | 91,052 | 06 Jul 2026 | Direct |
| Michael Skynner | BCYC | Ordinary Shares | Sale | -0.34% | -$2,293 | $4.31 | -532 | 157,171 | 06 Jul 2026 | Direct |
| Kevin Lee | BCYC | Ordinary Shares | Sale | -0.29% | -$7,486 | $4.31 | -1,737 | 603,671 | 06 Jul 2026 | Direct |
| Michael Charles Ferguson Hannay | BCYC | Ordinary Shares | Sale | -0.27% | -$1,099 | $4.31 | -255 | 94,375 | 06 Jul 2026 | Direct |
| Travis Alvin Thompson | BCYC | Ordinary Shares | Sale | -0.16% | -$448 | $4.31 | -104 | 64,441 | 06 Jul 2026 | Direct |
| Jennifer Scott Perry | BCYC | Ordinary Shares | Sale | -1.12% | -$4,424 | $4.27 | -1,036 | 91,428 | 02 Jul 2026 | Direct |
| Michael Skynner | BCYC | Ordinary Shares | Sale | -1.17% | -$7,938 | $4.27 | -1,859 | 157,703 | 02 Jul 2026 | Direct |
| Kevin Lee | BCYC | Ordinary Shares | Sale | -0.97% | -$25,214 | $4.27 | -5,905 | 605,408 | 02 Jul 2026 | Direct |
| Michael Charles Ferguson Hannay | BCYC | Ordinary Shares | Sale | -1.57% | -$6,431 | $4.27 | -1,506 | 94,630 | 02 Jul 2026 | Direct |
| Travis Alvin Thompson | BCYC | Ordinary Shares | Sale | -1.25% | -$3,497 | $4.27 | -819 | 64,545 | 02 Jul 2026 | Direct |
| Michael Charles Ferguson Hannay | BCYC | Ordinary Shares | Sale | -0.26% | -$1,268 | $5.05 | -251 | 96,136 | 06 Apr 2026 | Direct |
| Travis Alvin Thompson | BCYC | Ordinary Shares | Sale | -0.16% | -$515 | $5.05 | -102 | 65,364 | 06 Apr 2026 | Direct |
| Jennifer Scott Perry | BCYC | Ordinary Shares | Sale | -0.4% | -$1,865 | $5.04 | -370 | 92,464 | 06 Apr 2026 | Direct |
| Kevin Lee | BCYC | Ordinary Shares | Sale | -0.28% | -$8,666 | $5.05 | -1,716 | 611,313 | 06 Apr 2026 | Direct |
| Michael Skynner | BCYC | Ordinary Shares | Sale | -0.33% | -$2,651 | $5.05 | -525 | 159,562 | 06 Apr 2026 | Direct |
| Michael Charles Ferguson Hannay | BCYC | Ordinary Shares | Sale | -1.55% | -$7,468 | $4.91 | -1,521 | 96,387 | 02 Apr 2026 | Direct |
| Travis Alvin Thompson | BCYC | Ordinary Shares | Sale | -1.21% | -$3,923 | $4.91 | -799 | 65,466 | 02 Apr 2026 | Direct |
| Jennifer Scott Perry | BCYC | Ordinary Shares | Sale | -1.11% | -$5,097 | $4.91 | -1,038 | 92,834 | 02 Apr 2026 | Direct |
| Kevin Lee | BCYC | Ordinary Shares | Sale | -0.96% | -$29,298 | $4.91 | -5,967 | 613,029 | 02 Apr 2026 | Direct |
| Michael Skynner | BCYC | Ordinary Shares | Sale | -1.16% | -$9,226 | $4.91 | -1,879 | 160,087 | 02 Apr 2026 | Direct |
| Travis Alvin Thompson | BCYC | Employee Stock Option (right to buy) | Award | 58,000 | 58,000 | 03 Feb 2026 | Direct | |||
| Travis Alvin Thompson | BCYC | Ordinary Shares | Sale | -1.65% | -$7,192 | $6.45 | -1,115 | 66,265 | 05 Jan 2026 | Direct |
| Michael Skynner | BCYC | Ordinary Shares | Sale | -1.98% | -$21,098 | $6.46 | -3,266 | 161,966 | 05 Jan 2026 | Direct |
| Michael Charles Ferguson Hannay | BCYC | Ordinary Shares | Sale | -2.36% | -$15,267 | $6.45 | -2,367 | 97,908 | 05 Jan 2026 | Direct |
| Alistair Milnes | BCYC | Ordinary Shares | Sale | -2.44% | -$22,067 | $6.46 | -3,416 | 136,717 | 05 Jan 2026 | Direct |
| Alethia Young | BCYC | Ordinary Shares | Sale | -4.74% | -$28,123 | $6.49 | -4,334 | 87,081 | 05 Jan 2026 | Direct |
| Kevin Lee | BCYC | Ordinary Shares | Sale | -1.74% | -$70,989 | $6.46 | -10,989 | 618,996 | 05 Jan 2026 | Direct |
| Travis Alvin Thompson | BCYC | Ordinary Shares | Sale | -1.92% | -$8,956 | $6.80 | -1,317 | 67,380 | 02 Jan 2026 | Direct |
| Travis Alvin Thompson | BCYC | Ordinary Shares | Award | 120.2% | 37,500 | 68,697 | 02 Jan 2026 | Direct | ||
| Travis Alvin Thompson | BCYC | Employee Stock Option (right to buy) | Award | 75,000 | 75,000 | 02 Jan 2026 | Direct | |||
| Michael Skynner | BCYC | Ordinary Shares | Sale | -1.81% | -$20,706 | $6.80 | -3,045 | 165,232 | 02 Jan 2026 | Direct |
| Michael Skynner | BCYC | Ordinary Shares | Award | 42.3% | 50,000 | 168,277 | 02 Jan 2026 | Direct | ||
| Michael Skynner | BCYC | Employee Stock Option (right to buy) | Award | 100,000 | 100,000 | 02 Jan 2026 | Direct | |||
| Michael Charles Ferguson Hannay | BCYC | Ordinary Shares | Sale | -2.74% | -$19,224 | $6.80 | -2,827 | 100,275 | 02 Jan 2026 | Direct |
| Michael Charles Ferguson Hannay | BCYC | Ordinary Shares | Award | 94.2% | 50,000 | 103,102 | 02 Jan 2026 | Direct | ||
| Michael Charles Ferguson Hannay | BCYC | Employee Stock Option (right to buy) | Award | 100,000 | 100,000 | 02 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.